On the basis of emerging data and the current understanding of minimally invasive surgery (MIS) for radical hysterectomy (RH) in women with cervical cancer, the Korean Society of Gynecologic Oncology, Korean Society of Obstetrics and Gynecology, and Korean Society of Gynecologic Endoscopy and Minimally Invasive Surgery support the following recommendations:
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• The results of the LACC trial, together with institutional data, should be discussed with patients before choosing MIS RH.
• MIS RH should be performed for optimal candidates according to the current practice guidelines by gynecologic oncologists who are skilled at performing MIS.
Keywords: Uterine Cervical Neoplasms; Hysterectomy; Minimally Invasive Surgical Procedures; Laparoscopy; Laparotomy Cervical cancer is the 4th most commonly diagnosed cancer (6.6% of the total cases) and the 4th leading cause of cancer death (7.5% of the total cancer deaths) in women worldwide [1] . In Korea, cervical cancer is the 7th most common female malignancy, and 3,582 cases of cervical cancers were newly diagnosed in 2015 [2] . According to National Comprehensive Cancer Network guidelines, the following are considered as standard surgical treatments for early-stage cervical cancers: a modified radical hysterectomy with pelvic lymph node dissection (PLND) in International Federation of Gynecology and Obstetrics (2009; FIGO) stage IA1 with lympho-vascular space invasion (LVSI) and IA2, and a RH with PLND with/ without para-aortic lymph node dissection in FIGO stage IB1 and IIA1 [3] . Previous iterations of the guidelines had indicated that RH could be performed either via open laparotomy or via minimally invasive surgery (MIS) with laparoscopic approaches (which can be robotically assisted) [3] [4] [5] . The Korean Society of Gynecologic Oncology also stated that laparoscopic or robotic RH can be performed in patients with stage IB-IIA cervical cancer in the 3rd edition of the practice guidelines for management of cervical cancer in 2016 [4] .
A recently published prospective randomized trial demonstrated that MIS RH is associated with lower rates of disease-free survival (DFS) and overall survival (OS) than open RH is [6] . Previously, several non-randomized studies have shown perioperative advantages [8] [9] [10] [11] [12] and similar oncologic outcomes of MIS RH compared to those of open RH [13] [14] [15] [16] . However, the LACC trial is the first randomized study which compared the survival outcomes of MIS and open RH in patients with cervical cancer. Although some controversies regarding insufficient surgeons' proficiency and a lack of effort to minimize tumor spillage in the MIS group still surround this study, the clinical impact of this LACC trial results cannot be denied.
All cervical cancer patients scheduled to undergo RH should be informed about the outcome of this LACC trial. MIS RH should be chosen to treat proper candidates according to the current practice guidelines, and it should be performed by gynecologic oncologists who are skilled at performing MIS. Furthermore, establishment of optimal indication for performing MIS based on the tumor size and surgical methods to minimize tumor destruction or intraperitoneal spillage during colpotomy is required to ensure the oncologic safety of MIS in cervical cancer.
